Clinical Trials Browser

niraparib × Breast × 1 year × Clear all

NCT05601440 2026-03-27

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04481113 2026-01-29

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

Phase 1 Completed

Unilateral Breast Neoplasms

NCT04991480 2026-01-27

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT03368729 2026-01-23

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1 Active not recruiting

BreastGastrointestinalGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT05169437 2025-10-29

PAVO

Phase 2 Terminated

22 enrolled 17 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Urologic Neoplasms, Endometrial Neoplasms

NCT04837209 2025-10-01

NADiR

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03945721 2025-09-29

UNITY

Phase 1 Active not recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04641247 2025-09-29

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

Phase 2 Recruiting

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT04584255 2025-07-28

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT04915755 2025-07-16

ZEST

Phase 3 Active not recruiting

40 enrolled 13 charts

Breast Neoplasms, Triple Negative Breast Neoplasms